シママツ　ユタカ   SHIMAMATSU Yutaka   島松　裕    所属   医学部 医学科（東京女子医科大学病院）    職種   助教
論文種別	総説
言語種別	英語
査読の有無	査読なし
表題	Fatty Pancreas: Its Potential as a Risk Factor for Pancreatic Cancer and Clinical Implications
掲載誌名	正式名：Cancers 略　 称：Cancers (Basel) ISSNコード：20726694/20726694
掲載区分	国外
巻・号・頁	17(11),pp.1765
著者・共著者	OTSUKA Nao, SHIMAMATSU Yutaka, HAKUTA Ryunosuke, TAKAYAMA Yukiko, NAKAI Yosuke
担当区分	2nd著者
発行年月	2025/05
概要	With the increasing use of imaging modalities such as ultrasonography, computed tomography, and magnetic resonance imaging, incidental findings of pancreatic abnormalities, including pancreatic cysts and fatty pancreas (FP), have become more common. FP, also referred to as pancreatic steatosis, intra-pancreatic fat deposition, or fatty pancreas disease, is characterized by the accumulation of fat in the pancreas. Although FP has been associated with metabolic syndromes such as obesity and diabetes, its clinical significance remains unclear. Recent evidence suggests that FP may play a role in pancreatic carcinogenesis. Metabolic disorders, including obesity, insulin resistance, and diabetes, have been implicated in the development of FP. Additionally, FP has been linked to an increased risk of pancreatic ductal adenocarcinoma (PDAC), possibly due to chronic inflammation, lipotoxicity, and an altered pancreatic microenvironment. While early detection of PDAC remains challenging, surveillance strategies for high-risk individuals, such as those with pancreatic cysts, new-onset diabetes, or a genetic predisposition, may be crucial. In this context, FP may be incorporated into this surveillance of high-risk individuals. Some pharmacological interventions, including glucagon-like peptide-1 (GLP-1) receptor agonists and sodium-glucose cotransporter-2 (SGLT2) inhibitors, have shown potential in reducing pancreatic fat accumulation, although further studies are needed to confirm their efficacy.
DOI	10.3390/cancers17111765
PMID	40507246